Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05873205 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Blood Cancer and Refractory Immune Cytopenias, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 7
- Study locations
NCT05873205 is a Phase 2 study of Blood Cancer and Refractory Immune Cytopenias that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants, below the 264-participant average among 12 other Blood Cancer trials with a reported enrollment target (95% lower). The trial reports 7 study locations across 2 states.
The verdict
NCT05873205, a Phase 2 study of Blood Cancer and Refractory Immune Cytopenias, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
Conditions Studied
Interventions
- BIOLOGICAL Isatuximab
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2026-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05873205
The ClinicalTrials.gov registry entry for NCT05873205 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 264-participant average among 12 other Blood Cancer trials with a reported enrollment target (95% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Blood Cancer appearing as the primary indexed condition, and to 1 intervention - of which Isatuximab is the first listed.
NCT05873205 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05873205 about?
NCT05873205 is a clinical study titled "Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation". The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
What is the current status of trial NCT05873205?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2023-07-21. Estimated completion is 2026-06-29.
What conditions does trial NCT05873205 study?
This clinical trial studies the following conditions: Blood Cancer, Refractory Immune Cytopenias.
What interventions are being tested in trial NCT05873205?
The interventions under investigation include: Isatuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05873205?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05873205 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
Pharmacogenomics for Better Treatment of Fungal Infections in Cancer
RECRUITING · Phase 2
-
Allogeneic Transplantation From Related Haploidentical Donors
COMPLETED · Phase 2
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.